Application and Prospects of BCL-2 Inhibitors in Acute Myeloid Leukemia
10.3971/j.issn.1000-8578.2025.25.0668
- VernacularTitle:BCL-2抑制剂在急性髓系白血病中的应用及展望
- Author:
Zhen YAO
1
;
Zheng LI
1
;
Shengli XUE
1
Author Information
1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
- Publication Type:SPECIALFEATURE
- Keywords:
BCL-2;
Venetoclax;
Acute myeloid leukemia;
Therapeutic strategy
- From:
Cancer Research on Prevention and Treatment
2025;52(12):980-987
- CountryChina
- Language:Chinese
-
Abstract:
Research into the molecular biology of acute myeloid leukemia (AML) has facilitated the identification of therapeutic targets and the development of corresponding molecularly targeted drugs. The advent of the BCL-2 inhibitor venetoclax (VEN) concludes 50 years of stagnant clinical progress in AML and ushered in a new era of targeted therapy for this disease. Treatment regimens based on VEN had been applied to older patients and individuals unsuitable for intensive chemotherapy initially, but extensive studies on intensive and non-intensive clinical regimens incorporating VEN have confirmed its potential applicability to a broader patient demographic. This article systematically reviews the mechanism of action, resistance mechanisms, and optimization strategies of VEN in the context of AML.
